Innovating for Better Health
Pharmaceuticals & Biotechnology
Executive Search
70+ C-Suite Placements in Pharma & Biotech — with an average 43 Days time-to-placement and a 12-month candidate guarantee.
70+
C-Suite Placementsin Pharma & Biotech
43 Days
Avg. Time-to-Placement
94%
Offer Acceptance Rate
12 Months
Candidate Guarantee
Is This Your Situation?
If any of these sound familiar, you're speaking to the right practice.
→Your flagship API manufacturing facility received a USFDA warning letter. The board needs a VP Quality who can lead remediation, manage the FDA re-inspection, and restore approval within 12 months.
→Your CDMO is scaling from $50M to $200M in revenue as global pharma companies shift manufacturing to India. You need a CEO who can manage global customer relationships and GMP-compliant capacity expansion simultaneously.
→Your biosimilar company's Head of R&D left to join a competitor mid-way through a critical Phase III trial. The timeline to file an ANDA cannot slip.
→Your pharma company is entering the US specialty market for the first time and needs a Head of International Business who has successfully launched products through the 505(b)(2) pathway.
Our Pharma & Biotech Track Record
Placing the Regulatory Scientists and Drug Development Experts India's Pharma Industry Cannot Source Openly
The most critical talent in pharmaceuticals and biotech does not appear on job boards. A Head of Regulatory Affairs who has personally shepherded 50+ ANDA filings through the US FDA, a Quality Assurance Director who has…
See how Gladwin International & Company helps India's leading organisations access hard-to-reach specialist talent in Pharma & Biotech — the profiles that never appear on job boards.
1,400+
Pharma & Biotech professionals mapped
24+
Specialist mandates placed in 36 months
18
Regulatory and research institutions in our network
Situation:
Top-10 Indian pharma company had received an FDA import alert on its largest API facility. Existing quality leadership was part of the problem. Board needed an external VP Quality to lead remediation with credibility.
Outcome:
Placed in 44 days. Led a 14-month remediation programme. Facility cleared FDA re-inspection with zero repeat observations. Import alert lifted. Revenue from US market restored to pre-alert levels.
Situation:
PE-backed CDMO with 3 manufacturing sites needed a CEO to lead international client acquisition and drive capacity utilisation from 62% to 85%. Previous CEO had a manufacturing-only background and struggled with commercial development.
Outcome:
Placed in 51 days. Won 8 new global pharma contracts in first year. Capacity utilisation reached 81%. Revenue grew 38% year-on-year.
Situation:
Indian biosimilar company preparing concurrent filings with CDSCO, EMA, and WHO needed a Head of Regulatory Affairs who could manage multi-jurisdiction dossier submissions and respond to regulatory queries within tight timelines.
Outcome:
Placed in 36 days. Successfully filed with all three regulators within 6 months. WHO prequalification received within 14 months. First international tender won within 18 months.
All client details anonymised. Specific mandates available for reference under NDA upon request.
Our Pharma & Biotech Practice
India is the world's largest provider of generic medicines — supplying 20% of global generic volume and 60% of global vaccine production. This global leadership position, combined with an accelerating domestic market, a growing innovation and biotech sector, and significant CDMO/CRO business opportunities, makes pharmaceutical and biotechnology one of the most dynamic and globally significant sectors in which we operate.
Our Pharma & Biotech practice at Gladwin International Leadership Advisors covers the complete pharmaceutical and life sciences value chain: innovator multinationals, Indian generic leaders, branded generics, biotech companies, vaccine manufacturers, CROs and clinical research organisations, CDMOs, and health-tech companies at the intersection of pharma and digital. We place C-suite and senior leaders across commercial, regulatory, scientific, manufacturing, and business development functions.
Critical to our practice is deep regulatory intelligence. Leaders in pharmaceuticals must navigate a complex matrix of global regulatory requirements (USFDA, EMA, WHO-GMP, CDSCO, ANVISA, PMDA) and our consultants understand the specific competency demands this creates. We have built strong relationships with regulatory affairs, quality assurance, and manufacturing excellence leaders who combine deep technical expertise with commercial acumen.
As a specialist regulatory and legal leadership in pharma, and as a source for CHRO search for pharma organisations.
The Pharma & Biotech Landscape Today
India's pharmaceutical market is $50 billion domestically, with $25 billion in exports. The US remains the largest export market, accounting for 30% of exports, though USFDA compliance pressures continue to be a leadership challenge. Biosimilars and specialty pharma are high-growth areas, with significant R&D investment by companies like Biocon, Serum, Cipla, Sun Pharma, and Dr. Reddy's. The CDMO business is surging, driven by global supply chain diversification away from China. Biotech and gene therapy are early-stage but attracting significant investment. Digital health integration — AI drug discovery, precision medicine, digital therapeutics — is creating new leadership roles at the intersection of pharma and technology.
Key Leadership Challenges in Pharma & Biotech
USFDA and EMA compliance — finding quality and regulatory leaders who can restore and maintain approval status for facilities under import alert or warning letter, one of the sector's most acute leadership demands
Biosimilars and specialty pharma commercialisation — moving from commoditised generics to branded specialty requires entirely new commercial leadership capabilities
CDMO scale-up — as global pharma companies diversify manufacturing into India, building world-class CDMO leadership with both technical excellence and customer relationship management
R&D and innovation leadership — transitioning from generic-follow business models to differentiated, IP-rich innovation pipelines requires a different type of scientific and commercial leadership
Digital transformation in pharma — AI-assisted drug discovery, clinical trial optimisation, and commercial analytics require technology-fluent leaders in a traditionally conservative sector
Market access and pricing — as governments globally drive price controls, finding leaders who can manage market access, pricing strategy, and government affairs with sophistication
Roles We Typically Place
Why Gladwin International Leadership Advisors for Pharma & Biotech
Comprehensive pharma network: Sun Pharma, Cipla, Dr. Reddy's, Lupin, Biocon, Aurobindo, Torrent, Glenmark, and 50+ pharma companies
MNC pharma India operations: Pfizer, Novartis, Roche, AstraZeneca, Abbott, and all major innovator companies
Regulatory affairs and quality specialisation — our most in-demand sub-practice given endemic USFDA compliance challenges
CDMO and CRO practice — placements at Divi's Laboratories, Syngene, Piramal, LifeSciences Pharma, Laurus Labs
Biotech and emerging therapeutics — track record with Serum Institute, Bharat Biotech, Biological E, and biotech startups
Organisations We Serve
Indian generic and branded pharma companies
Multinational pharma MNC India operations
CDMOs and contract manufacturing organisations
CROs and clinical research organisations
Biotech, biosimilar, and specialty pharma companies
Pharma & Biotech Leadership Assessment — “HELIX”
Eight dimensions calibrated for pharmaceutical and biotechnology leadership.
C-Suite Function Practices
Each function we place in Pharma & Biotech has a dedicated practice with sector-calibrated assessment.
Discuss a Pharma & Biotech Mandate
Confidential · No obligation
Response within 4 business hours · All enquiries handled by a senior practice partner · Strictly confidential
Geographic Coverage
Pharma & Biotech Executive Search by Location
Our Pharma & Biotech practice operates across India and key international markets. Explore location-specific leadership intelligence for your city.
USFDA compliance and quality leadership — one of India's most critical pharma leadership needs
CDMO and CRO practice — specialist coverage as India captures global manufacturing diversification
Biotech and biosimilar emerging practice — early mover in a high-growth sub-sector
Looking for a Pharma & Biotech Leader?
Our Pharma & Biotech practice is ready to help. Guaranteed placement · 12-month candidate guarantee · Affordable pricing for organisations across the value chain.
Frequently Asked Questions — Pharmaceuticals & Biotechnology Executive Search
Common questions about recruiting Pharmaceuticals & Biotechnology leadership in India.
Our Pharmaceuticals & Biotech practice combines deep scientific and commercial understanding with an extensive network of senior pharma leaders — spanning regulated markets, emerging markets, branded generics, API manufacturing, CDMO, medical affairs, and regulatory affairs. We assess candidates across both the scientific and commercial dimensions, understanding that pharma leadership requires fluency across R&D pipelines, regulatory strategy, global manufacturing quality, and complex commercial organisation management.
We fill the full leadership spectrum: CEO/MD, CFO, COO, Chief Scientific Officer, Head of R&D, Head of Regulatory Affairs, Head of Medical Affairs, Head of Clinical Operations, Head of Quality & Compliance, Head of Manufacturing, Head of Commercial Operations, Head of International Business, CHRO, and Board Directors. We serve Indian pharma majors, MNC pharma subsidiaries, biotech companies, CROs, CDMOs, and API manufacturers.
The most effective pharmaceutical leaders in India today combine regulatory mastery with commercial excellence. They navigate USFDA, EMA, and WHO audit environments while driving market share across branded generics, patented products, or API supply chains. Key competencies include quality culture leadership (critical in an era of USFDA warning letters), talent management in highly specialised scientific functions, and portfolio strategy across regulated and emerging markets. Increasingly, digital health and RWE (real-world evidence) fluency is becoming a differentiator.
Yes. Our pharma practice serves biotech startups, research institutions, gene therapy companies, biosimilar developers, and innovative drug discovery organisations. These mandates typically require leaders who combine scientific credibility with fundraising capability, board management skills, and the ability to build research cultures that attract top scientific talent. We maintain strong networks in India's growing biotech hubs — Hyderabad, Pune, Bengaluru, and Ahmedabad.
CEOs of mid-to-large Indian pharma companies typically earn ₹3–10 crore CTC with performance bonuses. Country heads of MNC pharma subsidiaries typically command ₹3–7 crore. Heads of R&D at major pharma companies typically earn ₹1.5–4 crore. Quality and Regulatory Affairs heads command a significant premium given the USFDA compliance environment, typically earning ₹1.5–3.5 crore. We provide current, role-specific pharma compensation benchmarks for every search mandate.